China National Accord Medicines Corp Ltd (200028) — Cash Flow Quality Index
China National Accord Medicines Corp Ltd (200028) has a Cash Flow Quality Index of -1.46x as of September 2025. Operating cash flow of HK$-424.00 Million is below net income of HK$291.12 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore China National Accord Medicines Corp Ltd (200028) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
China National Accord Medicines Corp Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for China National Accord Medicines Corp Ltd across 27 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 200028 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for China National Accord Medicines Corp Ltd (1998–2025)
Year-by-year earnings quality comparison for China National Accord Medicines Corp Ltd. For live market cap and the full company financial profile, see China National Accord Medicines Corp Ltd stock valuation.
| Year | Quality Index | Operating CF (HKD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.44x | HK$1.64 Billion | HK$1.14 Billion | ▼ -89.5% |
| 2024 | 13.80x | HK$3.27 Billion | HK$237.00 Million | ▲ +820.4% |
| 2023 | 1.50x | HK$2.94 Billion | HK$1.96 Billion | ▲ +3.8% |
| 2022 | 1.45x | HK$2.56 Billion | HK$1.77 Billion | ▲ +33.4% |
| 2021 | 1.08x | HK$1.66 Billion | HK$1.53 Billion | ▲ +24.1% |
| 2020 | 0.87x | HK$1.50 Billion | HK$1.72 Billion | ▼ -35.2% |
| 2019 | 1.35x | HK$2.00 Billion | HK$1.48 Billion | ▲ +37.4% |
| 2018 | 0.98x | HK$1.32 Billion | HK$1.35 Billion | ▼ -11.7% |
| 2017 | 1.11x | HK$1.29 Billion | HK$1.16 Billion | ▼ -3.3% |
| 2016 | 1.15x | HK$1.47 Billion | HK$1.28 Billion | ▼ -13.7% |
| 2015 | 1.33x | HK$1.05 Billion | HK$787.35 Million | ▲ +211.9% |
| 2014 | -1.19x | HK$-796.70 Million | HK$669.84 Million | ▼ -236.6% |
| 2013 | 0.87x | HK$465.03 Million | HK$534.22 Million | ▲ +30.0% |
| 2012 | 0.67x | HK$323.96 Million | HK$483.68 Million | ▼ -3.4% |
| 2011 | 0.69x | HK$227.32 Million | HK$327.82 Million | ▼ -57.2% |
| 2010 | 1.62x | HK$428.16 Million | HK$264.22 Million | ▲ +18.6% |
| 2009 | 1.37x | HK$270.85 Million | HK$198.26 Million | ▼ -10.0% |
| 2008 | 1.52x | HK$246.58 Million | HK$162.45 Million | ▲ +116.2% |
| 2007 | 0.70x | HK$87.70 Million | HK$124.91 Million | ▼ -70.0% |
| 2006 | 2.34x | HK$181.73 Million | HK$77.76 Million | ▼ -43.6% |
| 2005 | 4.15x | HK$148.28 Million | HK$35.77 Million | ▼ -15.4% |
| 2004 | 4.90x | HK$130.30 Million | HK$26.58 Million | ▼ -8.9% |
| 2003 | 5.38x | HK$81.22 Million | HK$15.11 Million | ▼ -20.1% |
| 2002 | 6.73x | HK$28.76 Million | HK$4.28 Million | ▲ +227.3% |
| 2001 | 2.06x | HK$71.16 Million | HK$34.61 Million | ▲ +130.7% |
| 1999 | 0.89x | HK$22.84 Million | HK$25.62 Million | ▲ +141.6% |
| 1998 | 0.37x | HK$5.21 Million | HK$14.12 Million | — |